STOCK TITAN
  1. Home
  2. News
  3. HSCS

HeartSciences Inc. - HSCS STOCK NEWS

Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.

Heart Test Laboratories, Inc., operating under the brand name HeartSciences (symbol: HSCS), is an innovative company at the forefront of medical technology. Specializing in Artificial Intelligence (AI)-powered solutions, HeartSciences aims to revolutionize the field of cardiac screening by enhancing the capabilities of ECGs/EKGs. By leveraging advanced AI algorithms, the company focuses on the early detection of heart disease, making it a vital tool in frontline or point-of-care clinical settings.

HeartSciences' flagship product, the MyoVista® wavECG™, employs cutting-edge AI technology to provide a more comprehensive cardiac assessment, helping healthcare providers diagnose conditions that conventional ECGs might miss. This innovation has the potential to significantly improve patient outcomes by enabling earlier and more accurate detection of heart conditions.

Recently, HeartSciences announced the granting of an Indian patent for its MyoVista® Wavelet Technology, which underscores the company's commitment to expanding its global footprint. The company's ongoing projects include refining its AI algorithms and expanding the use of its technology in various clinical settings to further solidify its position as a leader in cardiac care.

In financial terms, HeartSciences continues to attract investor interest, exemplified by its listing on Nasdaq (HSCS; HSCSW). The company actively engages with its shareholders, as evidenced by the recent reminder for shareholders to vote ahead of the 2023 Annual Meeting of Stockholders, scheduled for January 17, 2024.

HeartSciences' commitment to innovation and improving healthcare is further demonstrated by data showing that their MyoVista AI-ECG model significantly outperformed traditional methods like NT-proBNP and ARIC HF score in screening for Stage B Heart Failure. This breakthrough indicates substantial progress in cardiac care and patient management.

For investors and stakeholders, HeartSciences provides regular updates and maintains transparent communication channels. The company encourages visits to its website and social media platforms for the latest news and developments.

News

HeartSciences to Present at the LD Micro Invitational XIV Conference

Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, announced CEO Andrew Simpson's presentation at the LD Micro Invitational XIV Conference. The focus is on transforming ECGs/EKGs for early heart disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences
-
News

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Rhea-AI Summary
HeartSciences (NASDAQ: HSCS) presented a study showcasing the effectiveness of MyoVista wavECG in screening preoperative patients for LVDD at the 18th World Congress of Anesthesiologists. The study demonstrated 100% sensitivity in detecting LVDD, potentially reducing unnecessary referrals to echocardiography. MyoVista wavECG shows promise in transforming cardiovascular medicine and is set to be commercially available soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Rhea-AI Summary
HeartSciences, a medical technology company, reported Q3 FY2024 financial results showing a strengthened financial position, strategic shifts, and business highlights. Key accomplishments include acquiring AI-ECG algorithms from Mount Sinai, FDA pathway changes, and enhanced team recruitment. The company aims to lead the AI-ECG market with improved financials, extended cash runway, and clinical advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
earnings
News

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Rhea-AI Summary
HeartSciences (NASDAQ: HSCS) announces a study showing MyoVista AI-ECG model outperforms NT-proBNP and ARIC HF score in Stage B Heart Failure screening among type 2 diabetes patients. The study highlights the potential of AI-ECG technology to enhance heart disease detection and screening processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
-
News

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has received a patent grant from the Canadian Intellectual Property Office for its AI-ECG technology. The company aims to revolutionize heart disease detection, reduce treatment costs, and capitalize on the growing ECG market, with a projected value of $25 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.37%
Tags
none
-
News

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Rhea-AI Summary
HeartSciences appoints Dr. Partho P. Sengupta, a renowned cardiologist, to its Scientific Advisory Board. Dr. Sengupta brings vast experience and expertise in AI-ECG technology, enhancing HeartSciences' position in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
management
News

HeartSciences Expands its Scientific Advisory Board

Rhea-AI Summary
HeartSciences appoints Dr. Jordan B. Strom to its Scientific Advisory Board, enhancing expertise in AI-based medical devices and preparing for FDA submission of MyoVista device and cloud platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

HeartSciences Appoints New Scientific Advisory Board Member

Rhea-AI Summary
HeartSciences (HSCS) appoints Dr. Benjamin Glicksberg, an elite data scientist and lead investigator of AI algorithms licensed by the company, to its Scientific Advisory Board. The appointment follows the recent closing of agreements with Mount Sinai, covering an industry-leading portfolio of AI-based ECG/EKG algorithms, technologies, and patent rights for the screening and diagnosis of cardiovascular disease. The company aims to achieve significant milestones, including launching a hardware-agnostic cloud platform to deliver the AI-ECG algorithms licensed from Mount Sinai and obtaining FDA clearance for its MyoVista wavECG device. Dr. Glicksberg's expertise in machine learning, digital health, and bioinformatics is expected to contribute to expanding the clinical diagnostic capabilities of the ECG/EKG, transforming the early detection of heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
management
-
News

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) announced the results of the 2024 Annual Meeting of Shareholders, including the passing of important resolutions and an adjournment in respect of Proposal 7. Approximately 54.37% of the Company’s outstanding shares were represented at the meeting. The shareholders approved the re-election of director nominees, the issuance of shares of common stock, the Equity Incentive Plan, the independent registered public accounting firm, and amendments to the Company’s Certificate of Formation. Proposal 7, which aimed to lower the quorum for future meetings, was adjourned until February 15, 2024 due to insufficient votes. The reconvened Annual Meeting will be held virtually, and shareholders are encouraged to vote by February 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
none
News

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
none

FAQ

What is the current stock price of HeartSciences (HSCS)?

The current stock price of HeartSciences (HSCS) is $2.9 as of November 1, 2024.

What is the market cap of HeartSciences (HSCS)?

The market cap of HeartSciences (HSCS) is approximately 2.7M.

What is HeartSciences' primary focus?

HeartSciences focuses on using AI technology to transform ECGs/EKGs for the early detection of heart disease.

What is the MyoVista® wavECG™?

The MyoVista® wavECG™ is HeartSciences' flagship product that employs AI to provide comprehensive cardiac assessments.

When is the next Annual Meeting of Stockholders?

The next Annual Meeting of Stockholders is scheduled for January 17, 2024.

What recent patent has HeartSciences been granted?

HeartSciences was recently granted an Indian patent for its MyoVista® Wavelet Technology.

How does the MyoVista AI-ECG compare to traditional methods?

The MyoVista AI-ECG model significantly outperformed traditional methods like NT-proBNP and ARIC HF score in screening for Stage B Heart Failure.

Where can I find the latest updates about HeartSciences?

You can find the latest updates on HeartSciences' website and their social media platforms.

What stock exchange is HeartSciences listed on?

HeartSciences is listed on Nasdaq under the symbols HSCS and HSCSW.

What is the significance of HeartSciences' AI technology?

HeartSciences' AI technology enhances the diagnostic capabilities of ECGs/EKGs, leading to earlier and more accurate detection of heart conditions.

Who can participate in the upcoming Annual Meeting of Stockholders?

All shareholders on record of HeartSciences' outstanding shares of common stock and preferred stock as of November 20, 2023, are entitled to participate and vote.

How does HeartSciences engage with its shareholders?

HeartSciences maintains transparent communication and encourages shareholders to participate in meetings and stay informed through regular updates on their website and social media.

Stock HSCS logo
HeartSciences Inc.

Nasdaq:HSCS

HSCS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HSCS Stock Data

2.65M
910.00k
10.64%
1.07%
2.25%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
SOUTHLAKE